S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development Will Be Presenting at the Accredited Members Spring Micro Cap Investor Conference in Las Vegas (2013/2/25)|
|United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension (2013/4/11)|
|Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension (2013/4/29)|
|Pluristem Announces Scientific and Investment Conferences for April 2013 (2013/4/10)|
|Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine (2013/4/18)|
|Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013 (2013/4/30)|
|Pluristem Develops PLX-RAD Cells for Use in Hematology (2013/5/7)|
|Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury (2013/3/20)|
|United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension (2013/2/26)|
|CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13 (2013/2/13)|
Click above to view more mutual fund data and stats for psti - Pluristem Therapeutic.